Evidence map›Paper›PMID 40636700›Full record

ArticleFrontiers in oncology2025

Novel ALK gene mutation in inflammatory myofibroblastic tumor of the thyroid: a case report.

Yang Guangxu, Li Yao, Xie Jing, Liu Hongsheng

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yang GuangxuDepartment of Ultrasonography, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Li YaoDepartment of Pathology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Xie JingDepartment of Pathology, Rui-jin Hospital, Shanghai Jiao-tong University School of Medicine, Shanghai, China.
Liu HongshengDepartment of Radiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inflammatory myofibroblastic tumor (IMT) is a rare soft tissue neoplasm, exceptionally uncommon in the thyroid. Approximately 50%-70% of IMT cases exhibit ALK gene rearrangements or fusions, while ALK point mutations are rare. We report a novel ALK gene mutation, ALK-R395H, in a case of thyroid IMT and review the relevant literature. Case report: A 43-year-old female patient presented with a thyroid mass discovered two months prior. Ultrasound revealed a solid hypoechoic mass in the middle of the left thyroid lobe. Histopathology showed characteristic spindle cell proliferation with plasma cell and lymphocyte infiltration. Immunohistochemistry demonstrated strong expression of Vimentin and ALK-1 in spindle cells, focal SMA expression, and strong positivity for Galectin-3, PAX-8, and TTF-1. Next-generation sequencing identified mutations in NTRK1, GNAS, RB1, and ALK, with a G1184A mutation in ALK exon 5, resulting in a missense mutation ALK(p.R395H) in the extracellular domain, the function of which remains to be elucidated. The pathological diagnosis was thyroid IMT; however, strong expression of thyroid epithelial markers and the ALK mutation suggested possible thyroid carcinoma components or malignant potential. The patient underwent left thyroid lobectomy with isthmus resection, received no adjuvant therapy, and showed no recurrence after 37 months of follow-up. Conclusion: This case reports the discovery of the ALK-R395H mutation in thyroid IMT, providing new insights into its molecular characteristics.

Indexed as

ALK-positivecase reportgene mutationinflammatory myofibroblastic tumorthyroid

Identifiers

PMID40636700
PMCPMC12237923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.